Two Conflicting Prospective, RCTs on Warfarin PGx Provide No Definitive Guidance to Physicians | GenomeWeb

Originally published Nov. 22.

Doctors have been in a "should we or shouldn't we" conundrum with warfarin pharmacogenetic testing for years.

The US Food and Drug Administration has updated the label for the widely used anticoagulant twice, in 2007 and 2010, informing doctors that patients with certain variants of CYP2C9 and VKORC1 genes may require non-standard warfarin doses when they start therapy. Meanwhile, physician practice guidelines don't recommend genotyping patients ahead of prescribing them warfarin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.